Kyung Nam Pharm Corrects Rights Offering Record Date Due to Regulatory Request, Maintaining Severe Dilution Risk for Existing Shareholders
Kyung Nam Pharm has corrected the record date for its 19.1 billion KRW rights offering originally set for June 25 2026, canceling the shareholder register closure period due to a regulatory request to amend the securities registration statement, creating uncertainty in the offering timeline.
This correction increases the likelihood of delay or modification of the massive rights offering that would dilute existing shareholders by approximately 70 percent. The proposed issue price of 1735 KRW is slightly below the current market price of 1788 KRW, but the dilution remains a significant burden.
The stated purpose of the capital raise is operational funding, raising concerns about capital erosion rather than financial improvement. While lead manager SK Securities is a credible institution, the regulatory request for amendment indicates oversight risk.
[AI Summary]Kyung Nam Pharm's correction of the rights offering record date, driven by a regulatory request, does not alter the substantial dilution of 70 percent from the 19.1 billion KRW capital increase at a discount. The operational funding purpose without clear ROI may intensify downward pressure on the stock price.
KOSDAQ Filing Information
[Correction of Description] Shareholder Register Closure Period or Record Date Setting